22-May-2026
Solid Cash Position and Advancing Clinical Trials Define Compugen’s Q1 2026 Results
Market Chameleon (Mon, 18-May 7:45 AM ET)
Compugen Reports First Quarter 2026 Results
PRNewswire (Mon, 18-May 7:00 AM ET)
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
PRNewswire (Tue, 12-May 7:00 AM ET)
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
PRNewswire (Mon, 4-May 7:00 AM ET)
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
PRNewswire (Thu, 9-Apr 7:00 AM ET)
Market Chameleon (Mon, 2-Mar 6:15 AM ET)
Compugen Reports Fourth Quarter and Full Year 2025 Results
PRNewswire (Mon, 2-Mar 7:00 AM ET)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Compugen Ltd. - trades on the NASDAQ stock market under the symbol CGEN.
As of May 22, 2026, CGEN stock price climbed to $2.80 with 563,831 million shares trading.
CGEN has a beta of 1.33, meaning it tends to be more sensitive to market movements. CGEN has a correlation of 0.07 to the broad based SPY ETF.
CGEN has a market cap of $261.84 million. This is considered a Small Cap stock.
Last quarter Compugen Ltd. - reported $2 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $646,240 and met earnings estimates .
In the last 3 years, CGEN traded as high as $3.24 and as low as $.53.
The top ETF exchange traded funds that CGEN belongs to (by Net Assets): SPDW, GWX.
CGEN has outperformed the market in the last year with a return of +90.5%, while the SPY ETF gained +29.1%. In the last 3 month period, CGEN beat the market returning +60.9%, while SPY returned +8.4%. However, in the most recent 2 weeks CGEN has underperformed the stock market by returning -3.4%, while SPY returned +1.1%.
CGEN support price is $2.50 and resistance is $2.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEN shares will trade within this expected range on the day.
